Error loading player: No playable sources found

49667

Workshop One: Innovation in Formulation of Biologics

Date
January 23, 2023
This product is not available for individual purchase, but it is available as part of the following products:

Innovative approaches in the formulation of biologics will be shared in this session.  Topics covered will include exploring the strategies in the development of formulations to support co-formulation of drug products and different routes of administration.  The use of nanoparticles in the development and delivery of mRNA therapeutics as well as the use of application of novel freezing and drying technique will be explored.  The session will also include an interactive panel discussion following the presentations.  






Related Products

Thumbnail for Workshop One: Comparability for Novel Protein-based Modalities
Workshop One: Comparability for Novel Protein-based Modalities
The morning session will focus on comparability for novel protein-based modalities. The afternoon session will focus on comparability for mRNA vaccines and microbiome products…
Thumbnail for Parallel Session 6 - ICH Q14 and Q2(R2) Concepts and Enhanced Approaches to the Analytical Method Lifecycle
Parallel Session 6 - ICH Q14 and Q2(R2) Concepts and Enhanced Approaches to the Analytical Method Lifecycle
With the endorsement from ICH Management Committee in 2018 to introduce a new quality guideline for Analytical Development (ICH Q14) and a complementary revision of ICH Q2(R1) for Validation of Analytical Procedures, product owners will gain further guidance on enhanced approaches to analytical met…
Thumbnail for Plenary Session 4 - Resolving Complexity: Innovative Analytical Technologies for Characterization of Complex Modalities
Plenary Session 4 - Resolving Complexity: Innovative Analytical Technologies for Characterization of Complex Modalities
In-depth analytical characterization of biological drugs and vaccines is important to aid in their development, and innovation in analytical technologies is crucial for the advancement of complex modalities…
Thumbnail for Keynote Presentation
Keynote Presentation
Laura Sepp-Lorenzino, Ph.D. joined Intellia Therapeutics in 2019 as Chief Scientific Officer and is responsible for Research and Early Development. Intellia is harnessing CRISPR-based technologies to revolutionize the future of medicine…